Gain Access to exclusive preclinical content.
Complete the form below to gain access to mattis aliquet nunc aliquam tempor. We’ll assign a user name and password, then send you a link. Thanks!

Get Access Register

EXCLUSIVE PRECLINICAL CONTENT.
You must log in to access content on this page. Or click here to request access.
The PI3Kδ inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sjӧgren’s syndrome

Monika D.Scuron, Brittany L.Fay, Andrew J.Connell, JulianOliver, Paul A.Smith, "The PI3Kδ inhibitor parsaclisib ameliorates pathology and reduces autoantibody formation in preclinical models of systemic lupus erythematosus and Sjӧgren’s syndrome", International Immunopharmacology, Received 10 March 2021, Revised 15 June 2021, Accepted 18 June 2021, Available online 29 June 2021, https://doi.org/10.1016/j.intimp.2021.107904.